Drag a card by its title · ⚙ to size, swap or remove

The company

PTC Therapeutics, Inc.

PTCT · Nasdaq

Health CareBiotechnologyNot moving yet

PTCT stood above a rising 150-day average in 29 of the last 52 weekly readings, and has been out of that trend for the last 12 weeks. It is 16.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 12
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $95.7M
Officials’ trades on record: 7
Institutions holding: 413 (+17)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 29 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

7 disclosed lines: House 0, Senate 0, executive 7; 1 people.

Who	Did	Amount	Traded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Office	sold	$15k–$50k	29 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Office	bought	$15k–$50k	22 Jun 2026filed 22 Aug 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Office	bought	$15k–$50k	4 Jun 2026filed 22 Aug 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Office	sold	$50k–$100k	30 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Office	bought	$15k–$50k	4 Mar 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Office	bought	$50k–$100k	26 Feb 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Office	sold	$50k–$100k	26 Jan 2026filed 14 May 2026

Insiders

Buy orders, 12 months0

Sale orders, 12 months89

Buyers · sellers0 · 13

Who	Did	Shares	Traded
Michael SchmertzlerDirector	sold	2,118at $59.52	14 Oct 2026filed 16 Oct 2026
Michael SchmertzlerDirector	sold	382at $60.14	14 Oct 2026filed 16 Oct 2026
Mark Elliott BouldingEXEC. VP AND CLO	sold	192at $64.26	9 Oct 2026filed 13 Oct 2026
Michael SchmertzlerDirector	sold	2,447at $63.38	7 Oct 2026filed 9 Oct 2026
Michael SchmertzlerDirector	sold	53at $63.95	7 Oct 2026filed 9 Oct 2026
Mark Elliott BouldingEXEC. VP AND CLO	sold	435at $64.16	6 Oct 2026filed 7 Oct 2026
Mark Elliott BouldingEXEC. VP AND CLO	sold	1,638at $64.03	5 Oct 2026filed 7 Oct 2026
Glenn Md Phd Steele, Jr.Director	sold	12,000at $65.16	30 Sep 2026filed 2 Oct 2026
Michael SchmertzlerDirector	sold	9,624at $67.83	17 Sep 2026filed 18 Sep 2026
Michael SchmertzlerDirector	sold	376at $68.45	17 Sep 2026filed 18 Sep 2026
Michael SchmertzlerDirector	sold	2,994at $66.58	16 Sep 2026filed 18 Sep 2026
Michael SchmertzlerDirector	sold	7,006at $67.35	16 Sep 2026filed 18 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders413+17 on the quarter

New · exited68 · 50

Reported value$9.0B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
BlackRock, Inc.added · filed 7 Aug 2026	24,473,787$1.3B	+1,887,539+8.4%
STATE STREET CORPadded · filed 7 Aug 2026	9,928,160$433.6M	+1,069,750+12.1%
MONTANOVA CAPITAL, LLCunchanged · filed 14 Aug 2026	8,575,422$94.1M	00.0%
BVF INCunchanged · filed 14 Aug 2026	8,445,769$92.7M	00.0%
RTW INVESTMENTS, LPunchanged · filed 14 Aug 2026	7,746,415$631.9M	00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	7,655,291$348.0M	+193,350+2.6%
Jupiter Topco LLCnew · filed 14 Aug 2026	7,261,324$590.5M	+7,261,324
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026	6,258,052$416.6M	+222,656+3.7%
ARMISTICE CAPITAL, LLCreduced · filed 14 Aug 2026	4,749,395$127.7M	-1,061,054−18.3%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	4,437,334$204.6M	+193,104+4.5%

31 Mar 2023 – 30 Jun 2026

News

No headline names it lately.

Everyone who traded it

Michael Schmertzler Director · last 14 Oct 20264 · 12

Mark Elliott Boulding EXEC. VP AND CLO · last 9 Oct 20260 · 63

Glenn Steele Jr. Director · last 30 Sep 20260 · 2

Matthew B. Klein CHIEF EXECUTIVE OFFICER · last 4 Aug 20260 · 33

Donald J. Trump White House Office · last 29 Jul 20264 · 3

Hege Elisabeth Sollie-Zetlmayer Director · last 28 Jul 20260 · 0

Pierre Gravier CHIEF FINANCIAL OFFICER · last 14 Jul 20261 · 7

Mary L. Smith Director · last 9 Jul 20260 · 1

Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER · last 9 Jul 20260 · 57

Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER · last 17 Jun 20260 · 44

Eric Pauwels CHIEF BUSINESS OFFICER · last 10 Jun 20260 · 41

Lee Scott Golden EVP & CHIEF MEDICAL OFFICER · last 2 Apr 20260 · 15

Same industry

MRNA ModernaLeading+147%

IOVA Iovance BiotherapeuticsLeading+126%

ABCL AbCellera BiologicsLeading+60%

HALO Halozyme TherapeuticsLeading+46%

XERS Xeris Biopharma HoldingsLeading+38%

ENTX Entera BioLeading+37%

HELP Helus PharmaLeading+36%

XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 202550.1%

Free cash flow marginFY 2025 · to 31 Dec 202540.6%

Return on capital employedFY 2025 · to 31 Dec 202544.9%

Cash conversionFY 2025 · to 31 Dec 2025104%

Research spendFY 2025 · to 31 Dec 202526.3%

Share count trendFY 2025 · to 18 Feb 20261.6%

Cash and equivalentsFY 2025 · to 31 Dec 2025$984.6M

Free cash flowFY 2025 · to 31 Dec 2025$702.3M

Analyst forecasts

No analyst forecasts yet.